Drug Discovery World

JULY 22, 2024

Keir Loiacono , CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals.

Therapies 130

Therapies Engineering Treatment Pharma Companies 130

PPD

SEPTEMBER 16, 2024

The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. In a recent panel discussion at DIA Global , our experts explored how these elements are reshaping clinical research and drug discovery.

52

52

Drug Discovery World

AUGUST 30, 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. Improving patient experience within clinical trials and long term follow up.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery World

FEBRUARY 14, 2024

AlphaMedix is a targeted alpha therapy currently in Phase II clinical development, which consists of an SSTR-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. In the Phase I study, treatment was well-tolerated, with a response rate of 62.5%

Therapies 130

Therapies FDA Approval FDA Clinical Trials 130

Drug Discovery World

DECEMBER 8, 2023

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The post Partners explore NK cell therapy and bispecific antibodies combination appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Clinical Trials Engineering Clinical Development 130

Drug Discovery World

JANUARY 22, 2024

The UK is cementing its position as a global leader in cell and gene therapy (CGT), according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline. The UK has 84 drugs in clinical development, surpassing all other European countries, with 23 CGTs are already approved for patient use in the UK.

Therapies 130

Therapies Clinical Trials Trials Clinical Development 130

Drug Discovery World

MARCH 25, 2024

Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. We have been impressed by the scientific work carried out by the Cardior team, especially on CDR132L, which has a distinctive mode of action and potential to become a first-in-class therapy.”

Therapies 130

Therapies RNA Disease Trials 130

Drug Discovery World

JUNE 19, 2024

DDW Editor Reece Armstrong speaks to Jasminka Taleska , Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients. The post How ready are we for radioligand therapies? appeared first on Drug Discovery World (DDW).

Therapies 147

Therapies Treatment Regulations Production 147

Drug Discovery World

DECEMBER 4, 2023

Qnovia has announced positive results from its first in-human study of QN-01, an inhaled smoking cessation therapy. QN-01 is currently being evaluated in the US by the FDA’s Center for Drug Evaluation and Research (CDER) and in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).

Therapies 130

Therapies Treatment Pharmacokinetics Clinical Development 130

Drug Discovery World

FEBRUARY 1, 2024

Vivet is a clinical stage biotech company developing gene therapies for rare inherited metabolic disorders. CrisTauX will enable accelerated clinical development of VTX-806 upon completion of the programme. Vivet Therapeutics has received €4.9

Therapies 130

Therapies Treatment Disease Virus 130

Drug Discovery World

JANUARY 5, 2023

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. . The benchmark therapy uses a vector similar to that used in the only gene therapy approved for SMA.

Therapies 130

Therapies Medical Schools Clinical Development Pharmaceuticals 130

Drug Discovery World

OCTOBER 3, 2023

The US Food and Drug Administration (FDA) has announced a pilot programme with the aim of accelerating the development of novel drug and biological products for rare diseases. The post FDA pilot programme to boost rare disease therapies appeared first on Drug Discovery World (DDW).

FDA 130

FDA Disease Therapies Clinical Trials 130

Cytel

AUGUST 28, 2023

A clinical development plan — a comprehensive strategy for developing an investigational product through regulatory submission — is a critical component of drug development and helps ensure that new therapies are safe, effective, and of high quality.

Clinical Development 52

Clinical Development Drug Development Therapies Production 52

Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

DECEMBER 19, 2022

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. . The post Partnership to co-develop cell therapy for multiple myeloma appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Clinical Trials Engineering Clinical Development 130

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Vaccine 147

Vaccine Clinical Development Drugs Marketing 147

Drug Discovery World

DECEMBER 20, 2022

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). . The therapy was also recently approved by the FDA for patients in the US. . World’s most expensive drug.

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

MARCH 2, 2023

The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of the company’s cancer drug pipeline and the latest innovations in targeted oncology. The company anticipates the drug will enter Phase I clinical trials in 2024.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

DECEMBER 14, 2023

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. We are thrilled to see this level of clinical activity in such a heavily pre-treated patient population,” said John Houston, Chairperson, Chief Executive Officer and President at Arvinas.

Therapies 130

Therapies Trials Pharmacokinetics Treatment 130

Drug Discovery World

SEPTEMBER 20, 2022

SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). The post FDA approves gene therapy for rare neurological disorder appeared first on Drug Discovery World (DDW).

FDA Approval 130

FDA Approval FDA Therapies Hospitals 130

Drug Discovery World

JANUARY 25, 2024

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. cases per 100,000 population, Globocan). .”

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. Record breaking investments in 2021 fuel an industry on fire . billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? The deeper the understanding of product and process from a characterisation standpoint, the smoother the regulatory conversations and development pathway will be.” The solution?

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

DECEMBER 21, 2022

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO). .

Therapies 130

Therapies Pharmacokinetics Clinical Development Treatment 130

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The post Scleroderma drug gets fast-tracked in the US appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Drugs Therapies Treatment 130

Drug Target Review

JULY 31, 2023

Dear Readers, I am thrilled to announce the launch of our new series, “Beyond the Lab,” which promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Emerging Trends and Technologies The report highlights the latest emerging trends and technologies in cell and gene therapy.

Therapies 98

Therapies Disease Clinical Development Hospitals 98

Drug Discovery World

APRIL 3, 2024

million from the Spanish Research Agency (AEI), under the call for grants for Public-Private Collaboration Projects, to accelerate the development of an innovative treatment aimed at controlling disabling and lethal haemorrhage.

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

Drug Discovery World

SEPTEMBER 4, 2024

EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

JULY 12, 2024

Following the success of therapies like Ozempic, it’s no surprise that type 2 diabetes research is being prioritised by biopharmaceutical companies. High levels of cancellations at Phase II not only increase the costs of clinical development, but also have a knock-on effect on the rate at which new therapies reach patients.

Research 147

Research Clinical Trials Clinical Development Trials 147

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Vaccine 130

Vaccine Drugs Clinical Development Marketing 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

APRIL 14, 2023

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer.

Drug Development 130

Drug Development Drugs Clinical Trials Therapies 130

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Not failed drugs, but failed studies. As soon as drug developers can begin to develop conviction, momentum increases.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery World

JULY 5, 2024

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS).

Pharmaceuticals 264

Pharmaceuticals Clinical Development International Therapies 264

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349